Pegasys user fee goal
This article was originally published in Pharmaceutical Approvals Monthly
Roche is granted priority review status for its combination therapy of Pegasys (peginterferon alfa-2a) and ribavirin, establishing a user fee goal of December 2002. The firm submitted the BLA in June for treatment of chronic hepatitis C in patients without cirrhosis and patients with cirrhosis with compensated liver disease (Pharmaceutical Approvals Monthly, June 2002, p. 3
You may also be interested in...
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.
Enjoying a 5% sales rise, Bayer Consumer Health grew faster than the global market last year, with the company keen to repeat the performance in 2021.